Discovery of potential antipsychotic agents possessing pro-cognitive properties (Q42803307)

7 November 2017

Discovery of potential antipsychotic agents possessing pro-cognitive properties (English)

1 reference

7 November 2017

Jelveh Lameh

1

1 reference

7 November 2017

Krista McFarland

2

1 reference

7 November 2017

Jorgen Ohlsson

3

1 reference

7 November 2017

Fredrik Ek

4

1 reference

7 November 2017

Fabrice Piu

5

1 reference

7 November 2017

Ethan S Burstein

6

1 reference

7 November 2017

Ali Tabatabaei

7

1 reference

7 November 2017

Roger Olsson

8

1 reference

7 November 2017

Stefania Risso Bradley

9

1 reference

7 November 2017

Douglas W Bonhaus

10

1 reference

7 November 2017

15 November 2011

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

7 November 2017

1 reference

7 November 2017

385

1 reference

7 November 2017

3

1 reference

7 November 2017

313-323

1 reference

https://scigraph.springernature.com/pub.10.1007/s00210-011-0702-2

7 November 2017

0 references

cites work

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Aging, memory, and the cholinergic system: a study of dichotic listening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

The role of 5-HT2A receptors in antipsychotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Muscarinic agonists for the treatment of cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Human Serial Learning: Enhancement with Arecholine and Choline Impairment with Scopolamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Discovery of an ectopic activation site on the M(1) muscarinic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Schizophrenia: from phenomenology to neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00210-011-0702-2

21 January 2018

12 December 2020

Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials

1 reference

12 December 2020

The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.

1 reference

12 December 2020

Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia"

1 reference

12 December 2020

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

12 December 2020

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

1 reference

12 December 2020

The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study

1 reference

12 December 2020

The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia.

1 reference

12 December 2020

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

10.1007/S00210-011-0702-2

Identifiers

DOI

1 reference

release_deyq5lmyezgfhd243tytfbxwam

7 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/deyq5lmyezgfhd243tytfbxwam

24 November 2022

mapped directly with Wikidata item

1 reference